Search

Displaying results 5841 - 5850 of 7540 in total
  1. Drug

    5-fluorouridine

    go.drugbank.com/drugs/DB01629
    Investigational

    This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase.

  2. Drug

    INM004

    go.drugbank.com/drugs/DB17791
    Investigational

    INM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic

  3. Drug

    Dextromethadone

    go.drugbank.com/drugs/DB15198
    Investigational

    Dextromethadone is under investigation in clinical trial NCT00588640 (Study of D-Methadone in Patients With Chronic Pain).

    Categories: Analgesics, Non-Narcotic
  4. Drug

    Altropane

    go.drugbank.com/drugs/DB04947
    Investigational

    Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and

  5. Drug

    Methadyl acetate

    go.drugbank.com/drugs/DB01433
    ExperimentalIllicit

    A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Monoctanoin

    go.drugbank.com/drugs/DB06801
    Experimental

    Monoctanoin is used to dissolve cholesterol gallstones.

  7. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006.

  8. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  9. Drug

    GO-203-2C

    go.drugbank.com/drugs/DB15008
    Investigational

    GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).

  10. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells.